Adoption of Memorandum of Association (MOA) and Articles of Association (AOA) as per Companies Act, 2013.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma reported FY2026 revenue of Rs 77,166 lakhs, up 16.6% from Rs 66,151 lakhs in FY2025. However, profit after tax declined 13.3% to Rs 4,105 lakhs from Rs 4,735 lakhs. EBITDA margin compressed to 8.56% from 10.64% year-on-year. Operating cash flow turned negative at Rs 301 lakhs (vs positive Rs 3,712 lakhs in FY2025) due to inventory buildup of Rs 7,327 lakhs and higher trade receivables. The board declared dividend of Rs 1.50/share (30% payout), appointed new internal auditors RMJ & Associates LLP, and recommended re-election of two directors. Promoter group shareholders holding 0.95% (9.5 lakh shares) sought re-classification to public category. Auditors issued an unmodified opinion. Bonus shares (1:1) were issued in July 2025.
Revenue growth is below 20%, while PAT declined and margins compressed significantly. Negative operating cash flow despite positive net profit is a concern, suggesting working capital pressure. Clean audit and dividend provide some support. The inventory surge and receivables growth warrant monitoring.